This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTPH Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH) Get TTPH alerts:Sign Up Key Stats Today's Range$2.18▼$2.2750-Day Range$2.20▼$2.2052-Week Range$0.56▼$8.60Volume282,689 shsAverage Volume932,542 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts. Read More Receive TTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TTPH Stock News HeadlinesInfinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News SummaryFebruary 26, 2023 | benzinga.comTetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test ResultsAugust 30, 2022 | thestreet.comHow to get compound interest working on your portfolioI’ve narrowed the entire S&P 500 down to the dividend stocks I’d actually buy myself — including two I’ve already invested $50,000 into — and you can see them all in my free Five Dividend Investing Cheat Sheets.October 13 at 2:00 AM | ProsperityPub (Ad)Tetraphase Executive Profits Hours Before Stock PlummetsAugust 20, 2022 | thestreet.comTTPH_old Historical DataApril 4, 2022 | investing.com10 Worst NASDAQ Biotech Stocks in the Third QuarterJanuary 16, 2022 | thestreet.comSee More Headlines TTPH Stock Analysis - Frequently Asked Questions How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping analysts' consensus estimates of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.45 million. Tetraphase Pharmaceuticals had a negative net margin of 798.18% and a negative trailing twelve-month return on equity of 210.86%. When did Tetraphase Pharmaceuticals' stock split? Tetraphase Pharmaceuticals shares reverse split before market open on Friday, September 27th 2019.The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Tetraphase Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), GE Aerospace (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/07/2020Today10/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TTPH CIK1373707 Webwww.tphase.com Phone617-715-3600FaxN/AEmployees119Year FoundedN/AProfitability EPS (Trailing Twelve Months)($22.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.08 million Net Margins-798.18% Pretax MarginN/A Return on Equity-210.86% Return on Assets-121.73% Debt Debt-to-Equity Ratio0.06 Current Ratio3.66 Quick Ratio3.56 Sales & Book Value Annual Sales$7.38 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.68 per share Price / Book0.33Miscellaneous Outstanding Shares7,263,000Free FloatN/AMarket Cap$15.98 million OptionableOptionable Beta2.33 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:TTPH) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tetraphase Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tetraphase Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.